COMMUNIQUÉS West-GlobeNewswire

Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
27/09/2024
SAN FRANCISCO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that Cory R. [...]
DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
27/09/2024
Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death 1 Phase 3 CEPHEUS study results presented in late-breaking oral [...]
Communities Across the Commonwealth Come Together to Celebrate Massachusetts Good Neighbor Day of Action
27/09/2024
-- A broad range of inspiring events including a “Find Your People” fair, intergenerational dinners, a town scavenger hunt, free YMCA admission, and others help people and communities connect-- BOSTON, Sept. 27, 2024 ( [...]
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
27/09/2024
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O [...]
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
27/09/2024
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and [...]
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
27/09/2024
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype [...]
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
27/09/2024
Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un [...]
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27/09/2024
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding [...]
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27/09/2024
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001’s potential to offer a [...]
Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
27/09/2024
TAMPA, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a top-rated addiction treatment facility since 1987, is proud to announce that it is now in-network with Blue Cross Blue Shield, effective September [...]
Burning Rock Announces Changes to Management and Board of Directors
27/09/2024
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in [...]
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
27/09/2024
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the [...]
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
27/09/2024
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
27/09/2024
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film Outlines the development strategy for the Company’s [...]
TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
27/09/2024
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing , s upporting the combinability of the GPRC5 D bispecific antibody 1 Safety [...]
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
27/09/2024
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies 1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag [...]
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
27/09/2024
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to enable supplemental [...]
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
27/09/2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or [...]
33 Medical Wins 2024 Best Technology in Spine Award for Innovative NuvoDisc® Device
27/09/2024
Boca Raton, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- 33 Medical, Inc., a leader in cutting-edge spinal health innovations, is proud to announce that its NuvoDisc ® medical device has been awarded the prestigious 2024 Best [...]

Pages